Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients

Background. Current evidence indicates that statins increase the risk of new onset diabetes mellitus (NOD) and also deteriorate the glycemic control in patients with known diabetes mellitus (DM) after high-dose statin therapy. Aims. The aim of this review was to explore the effect of atorvastatin in...

Full description

Saved in:
Bibliographic Details
Main Authors: Angeliki M. Angelidi, Emelina Stambolliu, Konstantina I. Adamopoulou, Antonis A. Kousoulis
Format: Article
Language:English
Published: Wiley 2018-01-01
Series:International Journal of Endocrinology
Online Access:http://dx.doi.org/10.1155/2018/8380192
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850227035597701120
author Angeliki M. Angelidi
Emelina Stambolliu
Konstantina I. Adamopoulou
Antonis A. Kousoulis
author_facet Angeliki M. Angelidi
Emelina Stambolliu
Konstantina I. Adamopoulou
Antonis A. Kousoulis
author_sort Angeliki M. Angelidi
collection DOAJ
description Background. Current evidence indicates that statins increase the risk of new onset diabetes mellitus (NOD) and also deteriorate the glycemic control in patients with known diabetes mellitus (DM) after high-dose statin therapy. Aims. The aim of this review was to explore the effect of atorvastatin in causing NOD or deteriorating glycemic control in patients with DM. Methods. Two independent reviewers conducted the literature search, through PubMed database searching for articles published in English until April 2015, and only primary studies were included. Results. Of the 919 articles identified in our original search, 33 met the criteria for this review encompassing 1,951,113 participants. Twenty articles examined dysregulation of DM due to atorvastatin. Half of them showed that there was no significant change in glycemic control in patients treated with atorvastatin. Other studies showed that fasting plasma glucose and HbA1c levels were increased by atorvastatin. Thirteen articles examined if atorvastatin causes NOD. The majority of these articles showed that patients who used atorvastatin had a higher dose-dependent risk of developing NOD. Conclusion. This systematic review suggests that there is an association between atorvastatin treatment and NOD. Moreover, it showed that atorvastatin in high dose causes worsening of the glycemic control in patients with DM.
format Article
id doaj-art-55d6146c968a434f95c9b67b0be36498
institution OA Journals
issn 1687-8337
1687-8345
language English
publishDate 2018-01-01
publisher Wiley
record_format Article
series International Journal of Endocrinology
spelling doaj-art-55d6146c968a434f95c9b67b0be364982025-08-20T02:04:55ZengWileyInternational Journal of Endocrinology1687-83371687-83452018-01-01201810.1155/2018/83801928380192Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million PatientsAngeliki M. Angelidi0Emelina Stambolliu1Konstantina I. Adamopoulou2Antonis A. Kousoulis3Society of Junior Doctors, Athens, GreeceSociety of Junior Doctors, Athens, GreeceSociety of Junior Doctors, Athens, GreeceSociety of Junior Doctors, Athens, GreeceBackground. Current evidence indicates that statins increase the risk of new onset diabetes mellitus (NOD) and also deteriorate the glycemic control in patients with known diabetes mellitus (DM) after high-dose statin therapy. Aims. The aim of this review was to explore the effect of atorvastatin in causing NOD or deteriorating glycemic control in patients with DM. Methods. Two independent reviewers conducted the literature search, through PubMed database searching for articles published in English until April 2015, and only primary studies were included. Results. Of the 919 articles identified in our original search, 33 met the criteria for this review encompassing 1,951,113 participants. Twenty articles examined dysregulation of DM due to atorvastatin. Half of them showed that there was no significant change in glycemic control in patients treated with atorvastatin. Other studies showed that fasting plasma glucose and HbA1c levels were increased by atorvastatin. Thirteen articles examined if atorvastatin causes NOD. The majority of these articles showed that patients who used atorvastatin had a higher dose-dependent risk of developing NOD. Conclusion. This systematic review suggests that there is an association between atorvastatin treatment and NOD. Moreover, it showed that atorvastatin in high dose causes worsening of the glycemic control in patients with DM.http://dx.doi.org/10.1155/2018/8380192
spellingShingle Angeliki M. Angelidi
Emelina Stambolliu
Konstantina I. Adamopoulou
Antonis A. Kousoulis
Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients
International Journal of Endocrinology
title Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients
title_full Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients
title_fullStr Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients
title_full_unstemmed Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients
title_short Is Atorvastatin Associated with New Onset Diabetes or Deterioration of Glycemic Control? Systematic Review Using Data from 1.9 Million Patients
title_sort is atorvastatin associated with new onset diabetes or deterioration of glycemic control systematic review using data from 1 9 million patients
url http://dx.doi.org/10.1155/2018/8380192
work_keys_str_mv AT angelikimangelidi isatorvastatinassociatedwithnewonsetdiabetesordeteriorationofglycemiccontrolsystematicreviewusingdatafrom19millionpatients
AT emelinastambolliu isatorvastatinassociatedwithnewonsetdiabetesordeteriorationofglycemiccontrolsystematicreviewusingdatafrom19millionpatients
AT konstantinaiadamopoulou isatorvastatinassociatedwithnewonsetdiabetesordeteriorationofglycemiccontrolsystematicreviewusingdatafrom19millionpatients
AT antonisakousoulis isatorvastatinassociatedwithnewonsetdiabetesordeteriorationofglycemiccontrolsystematicreviewusingdatafrom19millionpatients